Abstract
Up-regulation of the epidermal growth factor receptor (EGFR) is critical for the loss of growth control in a variety of human cancers, including squamous cell carcinoma of the head and neck (SCCHN). Stimulation of EGFR results in activation of mitogenic signaling pathways including Signal Transducers and Activators of Transcription (STATs). Stat5 activation has been primarily demonstrated in hematopoietic malignancies. Gene disruption studies suggest potentially distinct functions of the Stat5 isoforms, Stat5a and Stat5b, which are encoded by two genes closely linked on human chromosome 17. To determine the function of Stat5 in SCCHN growth control, we studied the expression and constitutive activation of Stat5a and Stat5b in normal and transformed human squamous epithelial cells. Increased constitutive activation of Stat5 was detected in transformed compared with normal squamous cells. Blockade of TGF-α or EGFR, abrogated Stat5 activation. Targeting of Stat5b using antisense oligonucleotides inhibited SCCHN growth. In addition, SCCHN cells stably transfected with dominant negative mutant Stat5b failed to proliferate in vitro. In contrast, targeting of Stat5a using either antisense or dominant negative strategies had no effect on cell growth. These results suggest that TGF-α/EGFR-mediated autocrine growth of transformed epithelial cells is dependent on activation of Stat5b but not Stat5a.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Carlesso N, Frank DA, Griffin JD . 1996 J. Exp. Med. 183: 811–820
Carpenter G . 1992 FASEB J. 6: 3283–3289
Chai SK, Nichols GL, Rothman P . 1997 J. Immunol. 159: 4720–4728
Christensen ME, Therkildsen MH, Hansen BL, Albeck H, Hansen GN, Bretlau P . 1992 Eur. Arch. Otorhinolaryngol. 249: 243–247
Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G . 2000 Clin. Cancer Res. 6: 2053–2063
Copeland NG, Gilbert DJ, Schindler C, Zhong Z, Wen Z, Darnell Jr JE, Mui AL, Miyajima A, Quelle FW, Ihle JN et al . 1995 Genomics 29: 225–228
Darnell Jr JE . 1997 Science 277: 1630–1635
de Groot RP, Raaijmakers JA, Lammers JW, Jove R, Koenderman L . 1999 Blood 94: 1108–1112
Endo S, Zeng Q, Burke NA, He Y, Melhem MF, Watkins SF, Lango MN, Drenning SD, Huang L, Rubin Grandis J . 2000 Gene Ther. 7: 1906–1914
Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ . 1994 Science 265: 1093–1095
Gouilleux-Gruart V, Gouilleux F, Desaint C, Claisse JF, Capiod JC, Delobel J, Weber-Nordt R, Dusanter-Fourt I, Dreyfus F, Groner B, Prin L . 1996 Blood 87: 1692–1697
Grandis JR, Chakraborty A, Zeng Q, Melhem MF, Tweardy D . 1998a J. Cell. Biochem. 69: 55–62
Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, Tweardy D . 1998b J. Clin. Invest. 102: 1385–1392
Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, Kim JD . 2000 Proc. Natl. Acad. Sci. USA 97: 4227–4232
Grandis JR, Melhem MF, Barnes EL, Tweardy D . 1996a Cancer 78: 1284–1292
Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ . 1998c J. Natl. Cancer Inst. 90: 824–832
Grandis JR, Tweardy DJ . 1993a Cancer Res. 53: 3579–3584
Grandis JR, Tweardy DJ . 1993b J. Cell. Biochem Suppl., ?? 188–191
Grandis JR, Zeng Q, Tweardy DJ . 1996b Nat. Med. 2: 237–240
Hayakawa F, Towatari M, Iida H, Wakao H, Kiyoi H, Naoe T, Saito H . 1998 Br. J. Haematol. 101: 521–528
Heo DS, Snyderman C, Gollin SM, Pan S, Walker E, Deka R, Barnes EL, Johnson JT, Herberman RB, Whiteside TL . 1989 Cancer Res. 49: 5167–5175
Hernandez-Sotomayor SM, Carpenter G . 1992 J. Membr. Biol. 128: 81–89
Ihle JN, Kerr IM . 1995 Trends Genet. 11: 69–74
Kazansky AV, Kabotyanski EB, Wyszomierski SL, Mancini MA, Rosen JM . 1999 J. Biol. Chem. 274: 22484–22492
Kazansky AV, Rosen JM . 2001 Cell Growth Differ. 12: 1–7
Kumar V, Bustin SA, McKay IA . 1995 Cell Biol. Int. 19: 373–388
Lacronique V, Boureux A, Monni R, Dumon S, Mauchauffe M, Mayeux P, Gouilleux F, Berger R, Gisselbrecht S, Ghysdael J, Bernard OA . 2000 Blood 95: 2076–2083
Lango MN, Shin DM, Grandis JR . 2001 Curr. Opin. Oncol. 13: 168–175
Levy DE, Gilliland DG . 2000 Oncogene 19: 2505–2510
Lin JX, Mietz J, Modi WS, John S, Leonard WJ . 1996 J. Biol. Chem. 271: 10738–10744
Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L . 1997 Genes Dev. 11: 179–186
Migone TS, Lin JX, Cereseto A, Mulloy JC, O'Shea JJ, Franchini G, Leonard WJ . 1995 Science 269: 79–81
Moriggl R, Gouilleux-Gruart V, Jahne R, Berchtold S, Gartmann C, Liu X, Hennighausen L, Sotiropoulos A, Groner B, Gouilleux F . 1996 Mol. Cell. Biol. 16: 5691–5700
Nieborowska-Skorska M, Slupianek A, Skorski T . 2000 Oncogene 19: 4117–4124
Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T . 1999 J. Exp. Med. 189: 1229–1242
Okuda K, Golub TR, Gilliland DG, Griffin JD . 1996 Oncogene 13: 1147–1152
Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE . 1999 J. Biol. Chem. 274: 17209–17218
Onishi M, Nosaka T, Misawa K, Mui AL, Gorman D, McMahon M, Miyajima A, Kitamura T . 1998 Mol. Cell. Biol. 18: 3871–3879
Rubin Grandis J, Chakraborty A, Melhem MF, Zeng Q, Tweardy DJ . 1997 Oncogene 15: 409–416
Sacks PG, Parnes SM, Gallick GE, Mansouri Z, Lichtner R, Satya-Prakash KL, Pathak S, Parsons DF . 1988 Cancer Res. 48: 2858–2866
Sadowski HB, Shuai K, Darnell Jr JE, Gilman MZ . 1993 Science 261: 1739–1744
Sattler M, Durstin MA, Frank DA, Okuda K, Kaushansky K, Salgia R, Griffin JD . 1995 Exp. Hematol. 23: 1040–1048
Schwaller J, Parganas E, Wang D, Cain D, Aster JC, Williams IR, Lee CK, Gerthner R, Kitamura T, Frantsve J, Anastasiadou E, Loh ML, Levy DE, Ihle JN, Gilliland DG . 2000 Mol. Cell 6: 693–704
Sexl V, Piekorz R, Moriggl R, Rohrer J, Brown MP, Bunting KD, Rothammer K, Roussel MF, Ihle JN . 2000 Blood 96: 2277–2283
Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK . 2001 Clin. Cancer Res. 7: 1204–1213
Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL . 1996 Oncogene 13: 247–254
Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF . 1999 Cell 98: 181–191
Soldaini E, John S, Moro S, Bollenbacher J, Schindler U, Leonard WJ . 2000 Mol. Cell. Biol. 20: 389–401
Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, Waxman DJ, Davey HW . 1997 Proc. Natl. Acad. Sci. USA 94: 7239–7244
Virolainen E, Carey TE, Wicha M, Krause CJ . 1983 Otolaryngol. Head Neck Surg. 91: 126–135
Wakao H, Gouilleux F, Groner B . 1994 EMBO J. 13: 2182–2191
Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, Mertelsmann R, Finke J . 1996 Blood 88: 809–816
Wong P, Severns CW, Guyer NB, Wright TM . 1994 Mol. Cell. Biol. 14: 914–922
Acknowledgements
This work was supported by National Institutes of Health grant CA77308 (to JR Grandis).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Leong, P., Xi, S., Drenning, S. et al. Differential function of STAT5 isoforms in head and neck cancer growth control. Oncogene 21, 2846–2853 (2002). https://doi.org/10.1038/sj.onc.1205385
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205385
Keywords
This article is cited by
-
Midazolam inhibits the proliferation of human head and neck squamous carcinoma cells by downregulating p300 expression
Tumor Biology (2014)
-
Microenvironmental genomic alterations reveal signaling networks for head and neck squamous cell carcinoma
Journal of Clinical Bioinformatics (2011)
-
Transcription factors: their potential as targets for an individualized therapeutic approach to cancer
Cancer Gene Therapy (2009)